FDA grants priority review to Pfizer TALZENNA-XTANDI combo in metastatic prostate cancer

Reuters2026/07/22 20:39

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

FDA accepted Pfizer’s priority review for TALZENNA with XTANDI in HRR-altered metastatic castration-sensitive prostate cancer.
PDUFA action date set for Q4 2026; approval would expand use from metastatic castration-resistant disease.
TALAPRO-3 data showed a 52% reduction in risk of radiographic progression or death versus placebo with XTANDI.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607221630BIZWIRE_USPR_____20260722_BW156396) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

FDA grants priority review to Pfizer TALZENNA-XTANDI combo in metastatic prostate cancer

You may also like

Crypto prices